vorinostat has been researched along with B-Cell Chronic Lymphocytic Leukemia in 7 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "In contrast, chronic lymphocytic leukemia (CLL) cells show constitutionally active Wnt signaling, which is associated with upregulated levels of pathway members such as Wnt3 and lymphoid enhancer-binding factor-1." | 1.40 | Trichostatin A effectively induces apoptosis in chronic lymphocytic leukemia cells via inhibition of Wnt signaling and histone deacetylation. ( Flamme, H; Gehrke, I; Hallek, M; Kreuzer, KA; Peiffer, L; Poll-Wolbeck, SJ, 2014) |
| "As a result, chronic lymphocytic leukemia cell migration in response to stromal cell-derived factor-1 (n=23, P<0." | 1.36 | The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis, down-regulates the CXCR4 chemokine receptor and impairs migration of chronic lymphocytic leukemia cells. ( Bron, D; De Bruyn, C; Delforge, A; Lagneaux, L; Meuleman, N; Stamatopoulos, B, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Peiffer, L | 1 |
| Poll-Wolbeck, SJ | 1 |
| Flamme, H | 1 |
| Gehrke, I | 1 |
| Hallek, M | 1 |
| Kreuzer, KA | 1 |
| Lu, K | 1 |
| Fang, XS | 1 |
| Feng, LL | 1 |
| Jiang, YJ | 1 |
| Zhou, XX | 1 |
| Liu, X | 1 |
| Li, PP | 1 |
| Chen, N | 1 |
| Ding, M | 1 |
| Wang, N | 1 |
| Zhang, J | 1 |
| Wang, X | 1 |
| Zhang, W | 1 |
| Pelicano, H | 1 |
| Yin, R | 1 |
| Zeng, J | 1 |
| Wen, T | 1 |
| Ding, L | 1 |
| Huang, R | 1 |
| Miller, CP | 1 |
| Rudra, S | 1 |
| Keating, MJ | 1 |
| Wierda, WG | 1 |
| Palladino, M | 1 |
| Chandra, J | 1 |
| Stamatopoulos, B | 1 |
| Meuleman, N | 1 |
| De Bruyn, C | 1 |
| Delforge, A | 1 |
| Bron, D | 1 |
| Lagneaux, L | 1 |
| Pérez-Perarnau, A | 1 |
| Coll-Mulet, L | 1 |
| Rubio-Patiño, C | 1 |
| Iglesias-Serret, D | 1 |
| Cosialls, AM | 1 |
| González-Gironès, DM | 1 |
| de Frias, M | 1 |
| de Sevilla, AF | 1 |
| de la Banda, E | 1 |
| Pons, G | 1 |
| Gil, J | 1 |
| Ralli, R | 1 |
| Banks, KM | 1 |
| Wiegmans, AP | 1 |
| Carney, D | 1 |
| Seymour, JF | 1 |
| Johnstone, RW | 1 |
| Alsop, AE | 1 |
7 other studies available for vorinostat and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
Trichostatin A effectively induces apoptosis in chronic lymphocytic leukemia cells via inhibition of Wnt signaling and histone deacetylation.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 7; Cell Survival; Drug Resistance, Neoplasm; Dr | 2014 |
The STAT3 inhibitor WP1066 reverses the resistance of chronic lymphocytic leukemia cells to histone deacetylase inhibitors induced by interleukin-6.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; bcl-X Protein; Cell Survival; Coculture Techn | 2015 |
Effective elimination of chronic lymphocytic leukemia cells in the stromal microenvironment by a novel drug combination strategy using redox-mediated mechanisms.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line | 2015 |
Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells.
Topics: Acetylation; Antioxidants; Apoptosis; Boronic Acids; Bortezomib; Caspase 8; Drug Synergism; Drug The | 2009 |
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis, down-regulates the CXCR4 chemokine receptor and impairs migration of chronic lymphocytic leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Movement; Down-Regulation; Histone Deacetylase Inhibitors; Hu | 2010 |
Analysis of apoptosis regulatory genes altered by histone deacetylase inhibitors in chronic lymphocytic leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Epigenesis, Genetic; Gene Expressio | 2011 |
Histone deacetylase inhibitors are unable to synergize with ABT-737 in killing primary chronic lymphocytic leukaemia cells in vitro.
Topics: Adult; Aged; Aged, 80 and over; Biphenyl Compounds; Drug Synergism; Female; Histone Deacetylase Inhi | 2012 |